GlassScriptPhysician profile
Jared L Dayton
NPI 1508816331
$3,765.61
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,155 · 2020: $707 · 2021: $1,302 · 2022: $568 · 2024: $33.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $645.51 | 2019-2022 | |
| Abbvie INC. | $403.41 | 2019-2022 | |
| Glaxosmithkline, LLC. | $342.32 | 2019-2022 | |
| Novo Nordisk INC | $311.81 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.49 | 2019-2022 | |
| Amgen INC. | $233.26 | 2019-2022 | |
| Pfizer INC. | $170.09 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $144.02 | 2019-2022 | |
| Allergan, INC. | $140.77 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $132.72 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $112.49 | 2020-2021 | |
| Lilly USA, LLC | $95.77 | 2019-2021 | |
| Antares Pharma, INC. | $90.27 | 2019-2022 | |
| Astellas Pharma US INC | $83.21 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $74.50 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.01 | 2019-2021 | |
| Amarin Pharma, INC. | $53.77 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $49.23 | 2021 | |
| Philips North America LLC | $40.05 | 2019 | |
| Exact Sciences Corporation | $33.92 | 2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $31.32 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $31.07 | 2019 | |
| Abbott Laboratories | $30.50 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $28.19 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.73 | 2022 | |
| Nevro Corp. | $19.19 | 2021 | |
| Esperion Therapeutics, INC. | $17.46 | 2020 | |
| Genentech USA, INC. | $17.20 | 2019 | |
| Sanofi Pasteur INC. | $16.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.89 | 2022 | |
| Horizon Therapeutics Plc | $15.53 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.78 | 2021 | |
| Lucid Diagnostics INC. | $13.97 | 2022 | |
| Mylan Specialty L.P. | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Dayton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.